Kymera Investor Day Presentation Deck
Tissue-Selective Degradation Drives Increase of Therapeutic Index
Kymera has
characterized an E3
ligase that is
expressed broadly
but NOT in ONE
blood cell type
●
A clinically validated
oncology target has
dose limiting
toxicity driven by
on-target
●
pharmacology in the
same blood cell type
where this E3 ligase
is absent/very low
E3 Ligase is Almost
Absent in One
Blood Cell Type
KYMERA
Tumor
Cells
Blood
Cells
©2021 KYMERA THERAPEUTICS, INC.
Donor
Donor 2
B-actin
This program is projected to nominate a
development candidate in 2022
E3 Ligase
Optimization
and
Degrader
Program
Percentage Control (%)
Percentage Control (%)
100
50-
Blood Cell Viability (%)
O
100
50
100-
50
0
0
0
KYMERA R&D DAY - December 16th, 2021
In Cancer Cell
2
3
Log₁0 [Concentration (nM)]
In Blood Cell
1
1
--● POI Degradation
2
3
Log₁0 [Concentration (nM)]
In Vivo
POI Degrader
POI SMI
4
Kymera's degrader
using this E3 ligase
degrades target in
cancer cells
Kymera's degrader
using this E3 ligase
DOES NOT degrade
target in one blood
cell type
In a pharmacologically
active dose in vivo a
degrader allows blood
cells to survive while SMI
leads to substantial cell
death
POI = protein target of interest
PAGE 91View entire presentation